Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Income (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Net Income for 13 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 128.47% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $29.4 million, a 160.49% increase, with the full-year FY2024 number at -$56.4 million, down 8.53% from a year prior.
  • Net Income was $3.6 million for Q3 2025 at Theravance Biopharma, down from $54.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $927.1 million in Q3 2022 to a low of -$79.7 million in Q1 2021.
  • A 5-year average of $46.1 million and a median of -$11.7 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: surged 1763.12% in 2022, then plummeted 254.32% in 2023.
  • Theravance Biopharma's Net Income stood at -$55.7 million in 2021, then skyrocketed by 106.99% to $3.9 million in 2022, then crashed by 329.84% to -$9.0 million in 2023, then crashed by 73.49% to -$15.5 million in 2024, then skyrocketed by 123.28% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Net Income are $3.6 million (Q3 2025), $54.8 million (Q2 2025), and -$13.5 million (Q1 2025).